2012 Brazilian Society of Rheumatology Consensus on vaccination of patients with rheumatoid arthritis
Visualizar/abrir
Data
2013Autor
Tipo
Outro título
Consenso 2012 da Sociedade Brasileira de Reumatologia sobre vacinação em pacientes com artrite reumatoide
Assunto
Abstract
Objective: To elaborate recommendations to the vaccination of patients with rheumatoid arthritis (RA) in Brazil. Method: Literature review and opinion of expert members of the Brazilian Society of Rheumatology Committee of Rheumatoid Arthritis and of an invited pediatric rheumatologist. Results and conclusions: The following 12 recommendations were established: 1) Before starting disease-modifying anti-rheumatic drugs, the vaccine card should be reviewed and updated; 2) Vaccines against seasona ...
Objective: To elaborate recommendations to the vaccination of patients with rheumatoid arthritis (RA) in Brazil. Method: Literature review and opinion of expert members of the Brazilian Society of Rheumatology Committee of Rheumatoid Arthritis and of an invited pediatric rheumatologist. Results and conclusions: The following 12 recommendations were established: 1) Before starting disease-modifying anti-rheumatic drugs, the vaccine card should be reviewed and updated; 2) Vaccines against seasonal infl uenza and against H1N1 are indicated annually for patients with RA; 3) The pneumococcal vaccine should be indicated for all patients with RA; 4) The vaccine against varicella should be indicated for patients with RA and a negative or dubious history for that disease; 5) The HPV vaccine should be considered for adolescent and young females with RA; 6) The meningococcal vaccine is indicated for patients with RA only in the presence of asplenia or complement defi ciency; 7) Asplenic adults with RA should be immunized against Haemophilus infl uenzae type B; 8) An additional BCG vaccine is not indicated for patients diagnosed with RA; 9) Hepatitis B vaccine is indicated for patients with RA who are negative for antibodies against HBsAg; the combined hepatitis A and B vaccine should be considered; 10) Patients with RA and at high risk for tetanus, who received rituximab in the preceding 24 weeks, should undergo passive immunization with tetanus immunoglobulin in case of exposure; 11) The YF vaccine is contraindicated to patients with RA on immunosuppressive drugs; 12) The above described recommendations should be reviewed over the course of RA. ...
Contido em
Revista brasileira de reumatologia. Campinas. Vol. 53, n. 1 (jan./fev. 2013), p. 4-23
Origem
Nacional
Coleções
-
Artigos de Periódicos (40711)Ciências da Saúde (10868)
Este item está licenciado na Creative Commons License